Bupropion withdrawal is real, though it has long been considered uncommon compared to the withdrawal syndromes associated with SSRIs and SNRIs. For years, prescribers treated bupropion as one of the “easier” antidepressants to stop, partly because its mechanism differs from serotonin-focused drugs and partly because large discontinuation studies simply did not focus on it. Case reports and growing clinical experience tell a more complicated story: some people who stop bupropion abruptly do experience a recognizable set of symptoms, and the safest approach is almost always a gradual taper rather than a sudden stop.
What Bupropion Withdrawal Feels Like
The symptoms people report after stopping bupropion overlap considerably with withdrawal from other antidepressants but tend to involve a mix of mood, physical, and sensory complaints. Common experiences include irritability, anxiety, headaches, nausea, sweating, insomnia, dizziness, and a pins-and-needles sensation called paresthesia. Some people also report palpitations and a general sense of feeling unwell that is hard to pin down. These symptoms have been documented in both adults and younger patients, and they appear to be connected to the abrupt changes in dopamine and norepinephrine signaling that bupropion was modulating while in the body.1PubMed Central. Bupropion-Associated Withdrawal Symptoms: A Case Report
The timeline can vary. With many antidepressants, withdrawal symptoms tend to peak around three weeks after stopping, based on research tracking standardized discontinuation scores across multiple drugs.2PubMed Central. Do withdrawal symptoms predict depression relapse after antidepressant cessation? Some people feel symptoms within a day or two of missing a dose, while others notice a slower onset over the first week. The intensity ranges from mildly annoying to genuinely disruptive, and duration can stretch from a few days to several weeks. There is no single universal experience, which is part of why bupropion withdrawal went underrecognized for so long.
Why Bupropion Gets a Reputation as “Easy to Stop”
Bupropion works primarily on dopamine and norepinephrine rather than serotonin, and this distinction matters. The antidepressants most notorious for causing withdrawal, such as paroxetine, venlafaxine, desvenlafaxine, and duloxetine, all act heavily on the serotonin system and tend to have short half-lives. A large pharmacovigilance analysis using the World Health Organization’s global adverse-event database found that short half-life antidepressants carried more than five times the risk of withdrawal syndrome reports compared to longer half-life drugs, with paroxetine, desvenlafaxine, venlafaxine, and duloxetine standing out as the highest risk.3PubMed Central. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database
Bupropion does not appear among those highest-risk drugs, and that comparison has shaped clinical thinking. Prescribers sometimes tell patients they can stop bupropion without much worry, or that a brief taper is sufficient. The problem is that “lower risk than paroxetine” is a low bar. Paroxetine is widely regarded as the hardest SSRI to discontinue. Being less problematic than the worst offender does not mean withdrawal is absent, and case reports make clear that some individuals do have a rough time stopping bupropion.4PubMed Central. Bupropion-Associated Withdrawal Symptoms Revisited: A Case Report
Another factor feeding the reputation is simply a lack of data. Most of the large antidepressant discontinuation studies focused on SSRIs and SNRIs because those classes dominate prescribing. Bupropion, being pharmacologically different, was often left out of head-to-head comparisons. Fewer studies means fewer documented cases, which gets mistaken for fewer actual cases.
Withdrawal Versus Relapse
One of the trickiest aspects of stopping any antidepressant is figuring out whether the symptoms you feel are withdrawal or a return of the underlying depression. This distinction matters because the response is different: withdrawal generally resolves on its own or with a brief reinstatement and slower taper, while relapse may require restarting treatment at a therapeutic dose for the long term.
Research tracking both withdrawal scores and depression scores after antidepressant discontinuation found that withdrawal symptoms peaked earlier than depressive symptoms, around day 22 versus day 28, but the two overlapped heavily. The scores were strongly correlated in the first few weeks, making it genuinely hard to separate them in a clinical setting.5PubMed Central. Do withdrawal symptoms predict depression relapse after antidepressant cessation? The same study found that withdrawal symptoms were not systematically misdiagnosed as relapse across the group, but the individual experience can still be confusing.
A few practical clues can help. Withdrawal symptoms often include physical sensations that depression alone would not explain, like dizziness, electric-shock feelings (sometimes called “brain zaps”), nausea, or paresthesia. If you experience those alongside low mood and irritability shortly after stopping bupropion, withdrawal is the more likely explanation. Symptoms that arrive weeks later and consist mainly of sadness, loss of interest, and fatigue without the physical component are more suggestive of relapse. Neither pattern is absolute, and anyone uncertain should talk to their prescriber rather than trying to diagnose it alone.
How to Taper Bupropion Safely
The simplest way to reduce withdrawal risk is to taper gradually rather than stopping all at once. Clinical reports on bupropion specifically recommend tapering to minimize the chance of symptoms.6PubMed Central. Bupropion-Associated Withdrawal Symptoms Revisited: A Case Report This advice aligns with what is known across all antidepressant classes: abrupt cessation consistently produces more withdrawal than gradual dose reduction.
Research on tapering speed across antidepressants has found that larger weekly dose cuts are associated with significantly more withdrawal symptoms than small daily reductions. One study comparing different approaches found that weekly drops averaging about a third of the previous dose produced more withdrawal than daily reductions of around 4 to 5 percent of the previous dose.7PubMed Central. Outcomes of hyperbolic tapering of antidepressants The principle is sometimes called hyperbolic tapering: instead of cutting the dose by the same fixed amount each time (say, from 300 mg to 150 mg to zero), the reductions get smaller as the dose gets lower. This reflects the fact that removing the last portion of a drug from a receptor system has a proportionally larger biological impact than removing the first portion at a high dose.
For bupropion specifically, a common clinical approach is stepping down from the extended-release 300 mg dose to 150 mg for a few weeks before stopping entirely. Some people need an even slower schedule, particularly if they have been on the medication for a long time or have previously experienced withdrawal from other drugs. There are no standardized bupropion taper protocols endorsed by major guidelines, so clinicians rely on general antidepressant tapering principles and adjust based on how the patient responds at each step.
If you are taking the sustained-release or extended-release formulation, do not crush or split tablets to achieve smaller dose reductions unless your prescriber has confirmed the specific product can be safely divided. Many extended-release formulations rely on their coating to control how the drug enters your bloodstream, and breaking them can release the full dose at once.
How Long You Have Been on Bupropion Matters
Duration of use is one of the strongest predictors of withdrawal difficulty across antidepressants. Someone who has taken bupropion for a few weeks is far less likely to experience withdrawal than someone who has been on it for years. The nervous system adapts to the presence of the drug over time, adjusting receptor sensitivity and neurotransmitter production. The longer those adaptations have been in place, the more the brain has to readjust when the drug disappears.
Dose also plays a role. Higher doses generally mean more neurochemical adaptation and a potentially bumpier discontinuation. Someone stopping 450 mg of bupropion after two years is in a different situation than someone stopping 150 mg after three months. Age and sex appear to influence withdrawal risk as well: the WHO pharmacovigilance analysis found that women had a modestly higher risk of reporting withdrawal syndrome overall, and that adults between 18 and 44 had the highest risk among age groups.8PubMed Central. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database
Previous experience with antidepressant withdrawal is another flag. If you had a difficult time stopping an SSRI in the past, you may be someone whose nervous system is more sensitive to medication changes in general, and a cautious bupropion taper is worth discussing with your prescriber.
The Smoking Cessation Angle
Bupropion is widely prescribed not just for depression but also as a smoking cessation aid, typically under the brand name Zyban. The courses used for quitting smoking are usually shorter, often 7 to 12 weeks, compared to the open-ended use common in depression treatment. This shorter duration makes withdrawal less likely, but it raises a different question: what happens to the smoking cessation benefits after bupropion is stopped?
A review of the major smoking cessation trials found that while bupropion produced meaningfully better quit rates during treatment, the picture became muddier after the medication ended. Some large trials showed sustained benefits at the one-year mark, but at least one trial found that the early advantage disappeared once treatment stopped. This has led researchers to suggest that bupropion may not permanently alter the brain’s response to nicotine and that its benefits are more closely tied to active treatment than to lasting neurochemical change.9PubMed Central. The use of bupropion SR in cigarette smoking cessation
For people using bupropion to quit smoking, the practical takeaway is that stopping the medication might coincide with increased cravings or a return of nicotine withdrawal symptoms that had been dampened by the drug. This is not the same as bupropion withdrawal in the antidepressant sense, but it can feel similar: irritability, anxiety, difficulty concentrating, and mood dips. Distinguishing between “my brain is readjusting to the absence of bupropion” and “my brain is demanding nicotine again” is not always possible from the inside, and in practice both processes may be happening simultaneously.
Genetics and How Your Body Processes Bupropion
Bupropion is primarily metabolized by an enzyme called CYP2B6, and genetic variation in this enzyme can meaningfully change how quickly your body clears the drug. People who metabolize bupropion slowly will have higher blood levels for longer after each dose, while fast metabolizers clear it quickly. This variation could plausibly affect withdrawal: someone who metabolizes the drug slowly may experience a more gradual natural taper when stopping, while a fast metabolizer might experience a sharper drop in drug levels.
Research on CYP2B6 genetics has focused mainly on how genotype affects bupropion’s efficacy rather than withdrawal specifically. One study of smokers found a striking difference: among people carrying a particular CYP2B6 variant, bupropion produced quit rates more than double those of placebo, while in people without that variant, bupropion performed no better than placebo at all.10PubMed Central. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial If genetic variation can change how well the drug works, it stands to reason that it could also change how the body responds when the drug is removed, though direct studies on genotype and bupropion withdrawal have not yet been done.
Drug interactions can mimic genetic effects here. Bupropion itself is a strong inhibitor of another enzyme, CYP2D6, which means it can affect the metabolism of many other medications. If you stop bupropion while taking another drug that CYP2D6 metabolizes, the levels of that second drug may rise because the inhibition is removed. This can produce new or worsening symptoms that look like bupropion withdrawal but are actually caused by changes in how the other medication is being processed. Anyone on multiple medications should coordinate discontinuation with a prescriber who can review the full drug list.
What Children and Adolescents Face
Bupropion is sometimes prescribed off-label for younger patients, particularly for ADHD or depression in adolescents. The withdrawal evidence in this age group is thin, largely because most discontinuation research has been conducted in adults. A systematic review of antidepressant deprescribing in children and adolescents confirmed that withdrawal symptoms in younger patients include irritability, anxiety, nausea, headaches, insomnia, dizziness, and paresthesia, mirroring the adult profile. The review emphasized that these symptoms are tied to how quickly the medication is cleared from the body and how the developing brain readjusts to changed dopamine and norepinephrine levels.11PubMed Central. Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms
Parents and caregivers should know that younger patients may have more difficulty articulating what they are experiencing. A teenager describing vague “weirdness” or increased crankiness after stopping a medication may be experiencing withdrawal that would be recognizable as such in an adult who could name the specific sensations. Gradual tapering is at least as important in this population as in adults, and arguably more so given the limited evidence base guiding clinicians on pediatric discontinuation.
When Symptoms Linger Longer Than Expected
Most discussions of antidepressant withdrawal assume symptoms resolve within a few weeks. For many people they do. But a subset of patients across all antidepressant classes, bupropion included, report symptoms that persist for months. This phenomenon, sometimes called protracted withdrawal or post-acute withdrawal syndrome, is poorly understood and contentious in psychiatry. Some clinicians attribute prolonged symptoms to relapse or underlying anxiety disorders rather than ongoing withdrawal, while patients often insist the symptoms feel qualitatively different from their original condition.
The difficulty is that no biomarker or test can definitively confirm withdrawal versus relapse versus a new condition. Clinicians are left relying on the pattern: Did the symptoms begin within days of dose reduction? Are they different in character from the original depression or anxiety? Do they include physical sensations like dizziness, paresthesia, or gastrointestinal upset that were not part of the original presentation? If the answers are yes, withdrawal remains a reasonable explanation even if the timeline stretches beyond what textbooks predict.
For anyone experiencing prolonged symptoms after stopping bupropion, reinstating a low dose and then tapering more slowly is one approach clinicians use. This is not guaranteed to work, and the evidence base consists mostly of case series and clinical experience rather than randomized trials. But it is a reasonable step before concluding that the original condition has relapsed and that long-term treatment is needed again. The key is not to make that decision in the first few weeks after stopping, when withdrawal and relapse are hardest to tell apart.